Abstract
A description of a structured group, held for anti-HIV positive haemophiliacs and their relatives, to discuss the implications of participating in the MRC/INSERM double-blind control trial of zidovudine is given. The group discussion is used to define, evaluate and rank the many treatment dilemmas inherent in participating in this drug trial.